Vienna, Austria

Friedrich Scheiflinger

This inventor holds 76 USPTO granted patents and 24 published patent applications, plus 14 CIPO patents and 35 EPO patents, primarily in Gene Therapy (CPC class A61K). Top assignees: Baxalta Gmbh, Baxter International Inc., Baxter Healthcare Sa. Active years: 1995-2023.

USPTO Granted Patents = 76 

% Patents Active = 82.9

 

 

Average Co-Inventor Count = 4.1

ph-index = 10

Forward Citations = 289(Granted Patents)

Forward Citations (Not Self Cited) = 250(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Orth/Donau, AT (1995 - 2001)
  • Vienna, AT (2005 - 2023)

Company Filing History:


Years Active: 1995-2023

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Gene Therapy
Viral Vectors
TFPI Inhibitors
Hemophilia A
Hemophilia B
Biologically Active Peptides
Coagulation Disease
Procoagulant Peptides
Immunoadsorption
Fibrinogen
Sulfated Polysaccharides
76 patents (USPTO):Explore Patents

Sure, I can help with that! Here's an article about inventor Friedrich Scheiflinger:

Title: Innovator Spotlight: Friedrich Scheiflinger, Pioneering Inventor from Vienna

Introduction:

Friedrich Scheiflinger, a prolific inventor based in Vienna, Austria, has made significant contributions to the fields of biochemistry and gene therapy through his groundbreaking patents. With an impressive portfolio of 76 patents, Scheiflinger continues to drive innovation in the medical and biotechnological sectors.

Latest Patents:

Scheiflinger's recent patents showcase his innovative approach to addressing critical medical needs. One of his latest inventions involves TFPI inhibitors and methods of use, which offer a novel solution for treating blood coagulation disorders and enhancing thrombin formation. Additionally, his work on viral vectors encoding recombinant FVIII variants with increased expression demonstrates his commitment to advancing gene therapy for hemophilia A patients.

Career Highlights:

Having worked with esteemed companies such as Baxalta GmbH and Baxter International Inc., Friedrich Scheiflinger has gained invaluable experience in the biopharmaceutical industry. His dedication to research and development has led to the successful commercialization of several life-saving therapies, solidifying his reputation as a visionary inventor in the field.

Collaborations:

Throughout his career, Scheiflinger has collaborated with top-tier professionals in the industry, including Michael Dockal and Peter Turecek. These partnerships have not only facilitated knowledge exchange and innovation but have also resulted in the development of cutting-edge technologies that have the potential to revolutionize healthcare practices worldwide.

Conclusion:

In conclusion, Friedrich Scheiflinger's exceptional talent, relentless pursuit of scientific excellence, and collaborative spirit have positioned him as a trailblazer in the realm of biotechnological innovations. His patented inventions continue to make a profound impact on the medical field, offering hope and improved treatment options for individuals suffering from various disorders. Scheiflinger's legacy as an inventor is defined by his unwavering commitment to pushing the boundaries of what is possible in medical research and biotechnology.

Feel free to reach out if you need more information about other inventors or patents!

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…